Multivariate analysis of clinical and biologic variables
| . | All patients . | Patients 60 years or younger . | ||||||
|---|---|---|---|---|---|---|---|---|
| OS . | DFS . | OS . | DFS . | |||||
| P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | |
| Age, y (≤ 60 vs > 60) | < .001 | 1.8 (1.4-2.3) | < .001 | 2.8 (1.9-4) | — | — | — | — |
| Karyotype (good vs intermediate and poor) | < .001 | .24 (.1-.5) | .004 | .26 (.1-.6) | .001 | .2 (.1-.5) | .02 | .2 (.04-.8) |
| WBC (≤ 20 × 109 WBC/L vs > 20 × 109WBC/L) | NS | — | NS | — | .05 | 1.4 (1-2) | NS | — |
| Status | ||||||||
| De novo | — | 1 | — | 1 | — | 1 | 1 | |
| AML from pre-existing MDS | .011 | 1.4 (1.1-1.9) | NS | — | .007 | 1.8 (1.2-2.9) | NS | — |
| tAML | .021 | 1.8 (1.1-2.9) | .005 | 3.1 (1.4-6.8) | .032 | 2 (1.1-3.9) | NS | — |
| FLT3 status | ||||||||
| wt | — | 1 | — | 1 | — | 1 | 1 | |
| ITD+ | NS | — | NS | — | NS | — | NS | — |
| TKD mut | NS | — | NS | — | NS | — | NS | — |
| ITD+/TKD mut | NS | — | NS | — | NS | — | NS | — |
| FLT3 mut/wt ratio 1 | ||||||||
| FLT3 ITD—vs mut/wt ratio greater than .784-150 | .002 | 1.8 (1.2-2.5) | < .001 | 3.2 (1.8-5.5) | NS | — | < .001 | 4.2 (2.1-8.3) |
| FLT3 mut/wt ratio 2 | ||||||||
| FLT3 ITD—vs mut/wt ratio greater than .954-150 | .001 | 2.3 (1.4-3.7) | < .001 | 8 (3.8-16.6) | NS | — | < .001 | 6.9 (3.3-14.8) |
| . | All patients . | Patients 60 years or younger . | ||||||
|---|---|---|---|---|---|---|---|---|
| OS . | DFS . | OS . | DFS . | |||||
| P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | P . | OR (95% CI) . | |
| Age, y (≤ 60 vs > 60) | < .001 | 1.8 (1.4-2.3) | < .001 | 2.8 (1.9-4) | — | — | — | — |
| Karyotype (good vs intermediate and poor) | < .001 | .24 (.1-.5) | .004 | .26 (.1-.6) | .001 | .2 (.1-.5) | .02 | .2 (.04-.8) |
| WBC (≤ 20 × 109 WBC/L vs > 20 × 109WBC/L) | NS | — | NS | — | .05 | 1.4 (1-2) | NS | — |
| Status | ||||||||
| De novo | — | 1 | — | 1 | — | 1 | 1 | |
| AML from pre-existing MDS | .011 | 1.4 (1.1-1.9) | NS | — | .007 | 1.8 (1.2-2.9) | NS | — |
| tAML | .021 | 1.8 (1.1-2.9) | .005 | 3.1 (1.4-6.8) | .032 | 2 (1.1-3.9) | NS | — |
| FLT3 status | ||||||||
| wt | — | 1 | — | 1 | — | 1 | 1 | |
| ITD+ | NS | — | NS | — | NS | — | NS | — |
| TKD mut | NS | — | NS | — | NS | — | NS | — |
| ITD+/TKD mut | NS | — | NS | — | NS | — | NS | — |
| FLT3 mut/wt ratio 1 | ||||||||
| FLT3 ITD—vs mut/wt ratio greater than .784-150 | .002 | 1.8 (1.2-2.5) | < .001 | 3.2 (1.8-5.5) | NS | — | < .001 | 4.2 (2.1-8.3) |
| FLT3 mut/wt ratio 2 | ||||||||
| FLT3 ITD—vs mut/wt ratio greater than .954-150 | .001 | 2.3 (1.4-3.7) | < .001 | 8 (3.8-16.6) | NS | — | < .001 | 6.9 (3.3-14.8) |
NS indicates not significant.
For these analyses separate models were used.